Cambridge Healthtech Institute’s 5th Annual
Opportunities, New Targets, Models and Tools, and Delivering Therapy to the Brain
June 19-20, 2019
Antibodies and new drugs that are promising for treating brain diseases and disorders are often limited by poor brain exposure. Research is focused on examining new ways to deliver drugs to the brain, including gene therapy and treatment of the BBB’s
microvessels. CHI’s 5th Annual Blood-Brain Barrier conference strives to bring you the hottest topics and biggest opportunities in discovery and development of highly efficacious therapeutic agents against CNS disorders and
innovative strategies for delivering therapies across the blood brain barrier (BBB). It will focus on the key areas of understanding BBB transport and dysfunction in disease through a series of case studies and cutting-edge research presentations.
This conference will address questions surrounding BBB permeability, blood flow, translational research, and biomarkers of BBB breakdown. Special attention will be paid to in vivo models and tools that are available to investigate BBB transport and
pathology in disease. The conference will also provide updates from the industry on antibody delivery and transport across the BBB.
Differentiation of Human Pluripotent Stem Cells into High Resistance Barrier-Endothelial Cells Using Genome Editing, Genomics and Chemogenomic Library Screening Approaches
Filip Roudnicky, PhD, Senior Scientist, Disease Relevant Cellular Assays, F. Hoffmann-La Roche Ltd.
In vitro and in vivo Models to Evaluate P-gp and BCRP Activity in Regulating BBB Penetration
Guangqing Xiao, PhD, Associate Director, DMPK, Takeda
Integrated Mapping of Pharmacokinetics and Pharmacodynamics in Brain Tumors
Nathalie Y.R. Agar, PhD, Associate Professor, Neurosurgery, Brigham and Women's Hospital
Molecular Mechanisms Governing the Formation and Regulation of the Blood Brain Barrier
Chenghua Gu, DVM. & PhD, Professor of Neurobiology, Harvard Medical School
Molecular Insight into Assessment of Unbound Drug Concentration in Brain Regions of Patients with Alzheimer’s Disease
Irena Loryan, PhD, Researcher, Department of Pharmaceutical Biosciences, Translational PKPD, Uppsala University
IGF1R-Targeting BBB Carrier Antibodies: MOA and Preclinical Assessment
Danica Stanimirovic, MD, PhD, Director, Translational Bioscience Department, Human Health Therapeutics Portfolio, National Research Council of Canada
Platform Technology for Treatment of Brain Disorders with Blood-Brain Barrier Penetrating Igg-Fusion Proteins: Preclinical and Clinical Update
Ruben Boado, PhD, Vice President, Research & Development/Co-Founder, ArmaGen, Inc.
For more details on the conference, please contact:Nandini KashyapConference DirectorCambridge Healthtech InstitutePhone: 781-972-5406Email: email@example.com
For partnering and sponsorship information, please contact:
Companies A-KRod EymaelBusiness Development ManagerCambridge Healthtech InstitutePhone: 781-247-6286Email: firstname.lastname@example.org
Companies L-ZJoseph Vacca, M.S.Director, Business Development Cambridge Healthtech InstitutePhone: 781-972-5431Email: email@example.com